SCHEMBL6495680

SCHEMBL6495680

CC(=O)N(Cc1ccccc1)[C@H]1CC[C@H](c2ccc(O)cc2)CC1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DPP4 P27487 1/20 0.49
DPP9 Q86TI2 1/20 0.49
DPP7 Q9UHL4 1/20 0.49
SLC6A2 P23975 2/20 0.45
SLC6A4 P31645 2/20 0.45
SLC6A3 Q01959 1/20 0.45
OPRM1 P35372 2/20 0.43
ESR2 Q92731 1/20 0.43
MMP1 P03956 1/20 0.42
MMP2 P08253 1/20 0.42
MMP3 P08254 1/20 0.42
MMP7 P09237 1/20 0.42
MMP13 P45452 1/20 0.42
UBE2M P61081 1/20 0.42
DCUN1D1 Q96GG9 1/20 0.42
AGER Q15109 3/20 0.41
MTNR1A P48039 1/20 0.41
CHRM2 P08172 1/20 0.41
CHRM3 P20309 1/20 0.41
LMNA P02545 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6495515 1.00 DPP4 (0.49) DPP4DPP9DPP7SLC6A2SLC6A4
SCHEMBL4799331 0.91 AGER (0.44) OPRM1ESR2UBE2MDCUN1D1AGER
SCHEMBL4799335 0.91 AGER (0.44) OPRM1ESR2UBE2MDCUN1D1AGER
SCHEMBL6482118 0.86 CCR5 (0.43) SLC6A2SLC6A4SLC6A3OPRM1ESR2
SCHEMBL6482121 0.86 CCR5 (0.43) SLC6A2SLC6A4SLC6A3OPRM1ESR2
SCHEMBL6486622 0.85 AGTR2 (0.47) OPRM1
SCHEMBL6486620 0.85 AGTR2 (0.47) OPRM1
SCHEMBL9272932 0.85 DPP4 (0.46) DPP4DPP9DPP7SLC6A2SLC6A4
SCHEMBL9272928 0.85 DPP4 (0.46) DPP4DPP9DPP7SLC6A2SLC6A4
SCHEMBL4801241 0.83 HSD11B1 (0.48) OPRM1UBE2MDCUN1D1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6919377-B2 Cyclohexylamine derivative as subtype selective NMDA receptor antagonists WARNER LAMBERT COMPANY LLC (US) 2005-07-19 US disclosed
US-20030236286-A1 Cyclohexylamine derivative as subtype selective nmda receptor antagonists DEORAZIO RUSSELL JOSEPH (US) 2003-12-25 US disclosed
EP-1278716-A1 CYCLOHEXYLAMINE DERIVATIVE AS SUBTYPE SELECTIVE NMDA RECEPTOR ANTAGONISTS WARNER-LAMBERT COMPANY (US) 2003-01-29 EP disclosed
WO-2001081295-A1 CYCLOHEXYLAMINE DERIVATIVE AS SUBTYPE SELECTIVE NMDA RECEPTOR ANTAGONISTS WARNER-LAMBERT COMPANY (US) 2001-11-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030236286-A1 Cyclohexylamine derivative as subtype selective nmda receptor antagonists GRIN1, GRIN2A, GRIN2B DPP4 3827/4885DPP9 3830/4885DPP7 3702/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.